Malignant tumor of biliary tract (disorder)
ABC-03 -
Year Started: 2011
Randomised phase II trial of cediranib (AZD2171) vs. placebo in addition to cisplatin / gemcitabine chemotherapy for patients with advanced biliary tract cancers
- Access:
- Access restricted at present
- Type:
- Clinical Trial
- Status:
- Completed
- Consent restrictions:
- Other animal work restriction, Outside EU access restriction, Xenograft restriction
| Associated Data Type | Procurement Timeframe |
|---|---|
| Biomarker datasets | 0 - 3 months |
| Clinical records | 0 - 3 months |
| Followup records | 0 - 3 months |
| Imaging data | 0 - 3 months |
| Pathology records | 0 - 3 months |
| Quality indicators | 0 - 3 months |
| Treatment records | 0 - 3 months |
Male
Adult (> 40 years)
11 - 100 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Tissue specimen | Surgical procedure (procedure) | RT | Paraffin | Not applicable | 0 - 10% |
Female
Adult (> 40 years)
11 - 100 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Peripheral blood mononuclear cells (PBMC) | -60°C to -85°C | N/A | Not applicable | 0 - 10% | |
| Plasma | -60°C to -85°C | N/A | Not applicable | 0 - 10% | |
| Tissue specimen | Surgical procedure (procedure) | RT | Paraffin | Not applicable | 0 - 10% |
Male
Adult (> 40 years)
11 - 100 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Peripheral blood mononuclear cells (PBMC) | -60°C to -85°C | N/A | Not applicable | 0 - 10% | |
| Plasma | -60°C to -85°C | N/A | Not applicable | 0 - 10% |